Cisplatin nephrotoxicity in children after continuous 72-h and 3×1-h infusions

Pediatric Nephrology

Volumn 16, Issue 7, 2001, Pages 586-593

  Erdlenbruch, B ^a   Pekrun, A ^a   Roth, C ^a   Grunewald, R W ^a   Kern, W ^a   Lakomek, M ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Administration rate; Chemotherapy; Children; Cisplatin; Nephrotoxicity; Pharmacokinetics

Indexed keywords

ALBUMIN; ALPHA 1 MICROGLOBULIN; CISPLATIN; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; N ACETYL BETA GLUCOSAMINIDASE;

ARTICLE; BOLUS INJECTION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE SEVERITY; DRUG ADMINISTRATION; DRUG BLOOD LEVEL; DRUG INFUSION; DRUG URINE LEVEL; FEMALE; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY INJURY; KIDNEY TUBULE DAMAGE; MALE; MEDULLOBLASTOMA; NEPHROTOXICITY; OSTEOSARCOMA; PARAMETER; PATHOLOGY; PHARMACOKINETICS; PRIORITY JOURNAL; PROTEINURIA; URINARY EXCRETION;

ADOLESCENT; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; CISPLATIN; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY DISEASES; KIDNEY GLOMERULUS; MALE; PLATINUM; PROTEINURIA;

EID: 0034951292     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004670100610     Document Type: Article

References (38)

1. Phase II evaluation of cisplatin in children with neuroblastoma and other malignant solid tumours
2. High complete response rate in children with advanced germ cell tumours using cisplatin-containing combination chemotherapy
3. Childhood tumors
4. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: Relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity
5. Plasma platinum levels: Relationship to cisplatin dose and nephrotoxicity
6. Cisplatin nephrotoxicity correlation with plasma platinum concentrations
7. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients
8. Nephrotoxicity of cis-dichlorodiammine platinum (II)
9. Cisplatin nephrotoxicity
10. Cisplatin nephrotoxicity
11. Partial reversibility of cisplatin nephrotoxicity in children
12. Assessment of chemotherapy-associated nephrotoxicity in children with cancer
13. Some effects of combination chemotherapy with cis-platinum on renal function in patients with nonseminomatous testicular carcinoma
14. Cisplatin pharmacokinetics in children with cancer
15. Cisplatin disposition in children and adolescents with cancer
16. Studies on age-dependent plasma platinum pharmacokinetics and ototoxicity of cisplatin
17. Continuous infusion of high-dose cisplatin in children: Pharmacokinetics of free and total platinum
18. A pharmacokinetic study of high-dose continuous infusion cisplatin in children with solid tumours
19. Model building in pharmacokinetics. Part III: Simplified rules for the deduction of analytical solutions for linear compartment models
20. Assessment of renal function in children
21. Clinical evaluation of sequentially scheduled cisplatin and VM26 in neuroblastoma: Response and toxicity
22. Renal toxicity of cisplatin in children
23. Effect of cis-diamminedichloroplatinum(II) on cultured human lymphoma cells and its therapeutic implications
24. 24-hour infusion of cis-platinum in head and neck cancers
25. A phase I trial of continuous infusion cisplatin
26. Phase I study of cis-diamminedichloroplatinum (II) administered as a constant 5-day infusion
27. cis-Diamminedichloroplatinum (II) by 5-day continuous infusion. A new dose schedule with minimal toxicity
28. Cisplatin dose rate as a risk factor for nephrotoxicity in children
29. Cisplatin administered as a continuous 5-day infusion: Plasma platinum levels and urine platinum excretion
30. Pharmacokinetic and toxicity evaluation of five-day continuous infusion versus intermittent bolus cis-diamminedichloroplatinum(II) in head and neck cancer patients
31. Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin
32. Pharmacokinetics of cisplatin in combined cisplatin and 5-fluorouracil therapy: A comparative study of three different schedules of cisplatin administration
33. Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma
34. Platinum organ toxicity and possible prevention in patients with testicular cancer
35. Clinically silent progressive renal tubulointerstitial disease during cisplatin chemotherapy
36. The effect of cisplatin on renal function in patients with testicular tumours
37. Ifosfamide, mesna and nephrotoxicity in children
38. Risk factors for nephrotoxicity after ifosfamide treatment in children: A UKCCSG late effects group study